In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney ...
In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...